This Week in Biotech: Brief Update

On pause for two weeks, back March 20.

Welcome back to This Week in Biotech by Biotech Blueprint.

Hi everyone, today’s edition is just a quick note. For personal and family reasons, I’m taking a short break from publishing for the next two weeks. I plan to be back with This Week in Biotech on March 20.

---

🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.

🌐 For consulting inquiries, please email me or visit BiotechBlueprintConsulting.com.

👥 And if you haven’t already, please connect with me or follow me on LinkedIn.

---

In the meantime, here are a few reader favorite episodes to catch up on.

1. Podcast (November 2025): Sensible Biotechnologies
   I sat down with Miro Gasparek (CEO) and Krishna Motheramgari (Principal Computational Scientist). Sensible is an Oxford-born, Y Combinator-backed startup betting that cell-based production will shape the next decade of mRNA.

Inside Sensible Biotechnologies: Reinventing mRNA Manufacturing

2. Podcast (December 2025): NImmune Biopharma
   I spoke with Dr. Josep Bassaganya-Riera (Founder and CEO) about building a late-stage immunology company in 2025, including raising capital in a tighter market, designing Phase 3 programs that match today’s regulatory expectations, and using artificial intelligence in ways that actually change decisions.

Inside NImmune’s Phase 3 Push in Ulcerative Colitis

3. Special episode (September 2025): mRNA therapeutics mini-series (part 1)
   I teamed up with Hartaj Singh (Biotech Capital Compass) to cover how ribonucleic acid became medicine, the engineering breakthroughs behind the coronavirus disease vaccines, and what might come next in infectious disease and oncology. We also discussed programs from Moderna and BioNTech, including personalized cancer vaccines.

The mRNA Revolution: Beyond COVID to Cancer, Flu & Herpes Vaccines

---

Thanks for your patience and for reading with Biotech Blueprint.

---

---

DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.

DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.

LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.